PDCD1 and breast carcinoma: To address these complexities, PD-L1 expression on the CTCs of metastatic breast cancer patients is actively under investigation as a predictive biomarker for PD-1/PD-L1 inhibition, potentially complementing or replacing PD-L1 detection on tumor cells and/or TILs in tumor tissue.